Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Arrowhead Pharmaceuticals, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
ARWR
Nasdaq
2830
arrowheadpharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Arrowhead Pharmaceuticals, Inc.
SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut
- May 7th, 2025 12:31 pm
Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences
- May 7th, 2025 11:30 am
Why Arrowhead Pharmaceuticals, Inc. (ARWR) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential
- May 5th, 2025 11:49 am
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results
- Apr 30th, 2025 8:01 pm
Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer
- Apr 15th, 2025 8:00 pm
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Apr 4th, 2025 8:30 pm
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is favoured by institutional owners who hold 70% of the company
- Mar 25th, 2025 10:02 am
Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases
- Mar 10th, 2025 6:02 pm
Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy
- Mar 10th, 2025 11:30 am
Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases
- Mar 6th, 2025 1:45 pm
Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)
- Feb 28th, 2025 2:00 pm
Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity
- Feb 25th, 2025 12:30 pm
Arrowhead Pharmaceuticals (ARWR): Among the Most Oversold Healthcare Stocks to Buy Now
- Feb 20th, 2025 5:15 pm
ARWR: Multiple Catalysts Ahead in 2025…
- Feb 12th, 2025 2:22 pm
Arrowhead Pharmaceuticals First Quarter 2025 Earnings: Misses Expectations
- Feb 12th, 2025 10:58 am
Q1 2025 Arrowhead Pharmaceuticals Inc Earnings Call
- Feb 11th, 2025 3:10 pm
Arrowhead Pharmaceuticals Inc (ARWR) Q1 2025 Earnings Call Highlights: Strategic Collaborations ...
- Feb 11th, 2025 7:06 am
Arrowhead Research: Fiscal Q1 Earnings Snapshot
- Feb 10th, 2025 9:08 pm
Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results
- Feb 10th, 2025 9:01 pm
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics
- Feb 10th, 2025 1:30 pm
Scroll